Inhibition of Melanoma Cell–Intrinsic Tim-3 Stimulates MAPK-Dependent Tumorigenesis
Authors:
- Tobias SchattonTSTobias Schatton
- Yuta ItohYIYuta Itoh
- Christina MartinsCMChristina Martins
- Erik RasbachERErik Rasbach
- Praveen SinghPSPraveen Singh
- Mariana SilvaMSMariana Silva
- Kyla MucciaroneKMKyla Mucciarone
- Markus V. HepptMHMarkus V. Heppt
- Jenna Geddes-SweeneyJGJenna Geddes-Sweeney
- Kate StewartKSKate Stewart
- Anne BrandenburgABAnne Brandenburg
- Jennifer LiangJLJennifer Liang
- 18 August 2022
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (20) , 3774-3784
Abstract
T-cell immunoglobulin mucin family member 3 (Tim-3) is an immune checkpoint receptor that dampens effector functions and causes terminal exhaustion of cytotoxic T cells. Tim-3 inhibitors are under investigation in immuno-oncology (IO) trials, because blockade of T-cell-Tim-3 enhances antitumor immunity. Here, we identify an additional role for Tim-3 as a growth-suppressive receptor intrinsic to melanoma cells. Inhibition of melanoma cell-Tim-3 promoted tumor growth in both immunocompetent and immunocompromised mice, while melanoma-specific Tim-3 overexpression attenuated tumorigenesis. Ab-mediated Tim-3 blockade inhibited growth of immunogenic murine melanomas in T-cell–competent hosts, consistent with established antitumor effects of T-cell-Tim-3 inhibition. In contrast, Tim-3 Ab administration stimulated tumorigenesis of both highly and lesser immunogenic murine and human melanomas in T-cell–deficient mice, confirming growth-promoting effects of melanoma-Tim-3 antagonism. Melanoma-Tim-3 activation suppressed, while its blockade enhanced, phosphorylation of pro-proliferative downstream MAPK signaling mediators. Finally, pharmacologic MAPK inhibition reversed unwanted Tim-3 Ab-mediated tumorigenesis in T-cell–deficient mice and enhanced desired antitumor activity of Tim-3 interference in T-cell–competent hosts. These results identify melanoma-Tim-3 blockade as a mechanism that antagonizes T-cell-Tim-3–directed IO therapeutic efficacy. They further reveal MAPK targeting as a combination strategy for circumventing adverse consequences of unintended melanoma-Tim-3 inhibition. Significance: Tim-3 is a growth-suppressive receptor intrinsic to melanoma cells, the blockade of which promotes MAPK-dependent tumorigenesis and thus counteracts antitumor activity of T-cell–directed Tim-3 inhibition.Keywords
All Related Versions
Funding Information
- National Institutes of Health (R01CA258637)
- National Institutes of Health (R01CA247957)
- National Institutes of Health (R01CA190838)
- V Foundation for Cancer Research
- Harvard Stem Cell Institute
- Outrun the Sun
- Melanoma Research Alliance
- Brigham Research Institute
- National Institutes of Health (U01CA225644)
- National Institutes of Health (R21AI146368)
- Deutsche Forschungsgemeinschaft
- Deutsche Forschungsgemeinschaft
- Arbeitsgemeinschaft Dermatologische Forschung
This publication has 35 references indexed in Scilit:
- Tim-3 Expression in Cervical Cancer Promotes Tumor MetastasisPLOS ONE, 2013
- The Glycan-Binding Protein Galectin-9 Has Direct Apoptotic Activity toward Melanoma CellsJournal of Investigative Dermatology, 2012
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- From genes to drugs: targeted strategies for melanomaNature Reviews Cancer, 2012
- Phosphotyrosine-Dependent Coupling of Tim-3 to T-Cell Receptor Signaling PathwaysMolecular and Cellular Biology, 2011
- Anti-TIM3 Antibody Promotes T Cell IFN-γ–Mediated Antitumor Immunity and Suppresses Established TumorsCancer Research, 2011
- Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell markerProceedings of the National Academy of Sciences, 2011
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunityJournal of Experimental Medicine, 2010
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patientsJournal of Experimental Medicine, 2010
- Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritisClinical Immunology, 2008